Literature DB >> 17786943

Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements.

Tiziana Tonini1, Giuseppina D'Andrilli, Alfredo Fucito, Leonardo Gaspa, Luigi Bagella.   

Abstract

An understanding of the mechanisms that uncover the dynamic changes in the distribution of the chromatin modifying enzymes and regulatory proteins on their target loci could provide further insight into the phenomenon of malignant transformation. Based on the current available data, it seems more and more clear that an abnormal expression of Ezh2, a member of the Polycomb group (PcG) protein, may be involved in the tumorigenesis process, in addition, different studies identify Ezh2 as a potential marker that distinguish aggressive prostate and breast cancer from indolent one. Recent investigation show that ectopic expression of Ezh2 provides proliferative advantage to primary cells through interaction with the pathways of key elements that control cell growth arrest and differentiation, like members of the retinoblastoma (Rb) family. Here, we outline how these pathways converge and we review the recent advances on the molecular mechanisms that promote cell cycle progression through deregulation of Ezh2 protein level, providing novel links between cancer progression and chromatin remodeling machineries. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17786943     DOI: 10.1002/jcp.21241

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  33 in total

1.  Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer.

Authors:  Qingshan Chang; Yadong Zhang; Kevin J Beezhold; Deepak Bhatia; Hongwen Zhao; Jianguo Chen; Vince Castranova; Xianglin Shi; Fei Chen
Journal:  J Hepatol       Date:  2008-10-16       Impact factor: 25.083

Review 2.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

Review 3.  Gene silencing and Polycomb group proteins: an overview of their structure, mechanisms and phylogenetics.

Authors:  Shahram Golbabapour; Nazia Abdul Majid; Pouya Hassandarvish; Maryam Hajrezaie; Mahmood Ameen Abdulla; A Hamid A Hadi
Journal:  OMICS       Date:  2013-06

Review 4.  Polycomb and the emerging epigenetics of pancreatic cancer.

Authors:  Adrienne Grzenda; Tamas Ordog; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2011-06

5.  Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma.

Authors:  Li-Ru He; Meng-Zhong Liu; Bin-Kui Li; Hui-Lan Rao; Yi-Ji Liao; Xin-Yuan Guan; Yi-Xin Zeng; Dan Xie
Journal:  BMC Cancer       Date:  2009-12-22       Impact factor: 4.430

Review 6.  Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Laura F Hutchins; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

Review 7.  Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.

Authors:  Duangmani Thanapprapasr; Wei Hu; Anil K Sood; Robert L Coleman
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 8.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

9.  MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.

Authors:  Paul Cao; Zhiyong Deng; Meimei Wan; Weiwei Huang; Scott D Cramer; Jianfeng Xu; Ming Lei; Guangchao Sui
Journal:  Mol Cancer       Date:  2010-05-17       Impact factor: 27.401

10.  Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.

Authors:  Max S Wicha
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.